MONOPAR THERAPEUTICS INC (MNPR) Stock Earnings & Estimates
NASDAQ:MNPR - US61023L2079 - Common Stock
44.93 USD
+2.15 (+5.03%)
44.93 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 2,594.74% | N/A 69.37% | N/A 114.12% | N/A 64.87% | N/A 45.06% | N/A 39.58% | ||||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.19M | -16.6M -1,294.96% | -3.33M 79.94% | -4.32M -29.73% | -6.51M -50.69% | -9.13M -40.25% | -10.54M -15.44% | -8.83M 16.22% | -16M -81.20% | N/A -0.14% | N/A -64.15% | N/A -16.81% | N/A 156.39% | N/A 80.63% | N/A 109.41% | N/A 34.62% | N/A 40.04% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -2.95 -48.32% | -3.70 -25.42% | -4.15 -12.16% | -3.05 26.51% | -4.12 -35.08% | N/A 55.44% | N/A -101.53% | N/A 35.08% | N/A 115.50% | N/A 190.41% | N/A 61.79% | N/A 54.52% | N/A 50.75% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.47 -26.35% | -0.61 77.81% | -0.58 -53.54% | -0.59 -67.86% | -0.74 -59.27% | -1.47 -141.67% |
| Revenue Q2Q % growth | 775.2K | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.149M -163.42% | -5.282M 52.31% | -5.604M -73.93% | -5.768M -78.33% | -6.836M -64.78% | -14.091M -166.79% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.35 30.00% | -0.48 | 0.13 | 27.30% |
| Q1 2025 Q2Q % growth | -0.38 24.00% | -0.69 | 0.31 | 45.21% |
| Q4 2024 Q2Q % growth | -2.75 -358.33% | -0.43 | -2.32 | -541.92% |
| Q3 2024 Q2Q % growth | -0.37 47.14% | -0.49 | 0.12 | 23.90% |
| Q2 2024 Q2Q % growth | -0.50 37.50% | -0.48 | -0.02 | -5.05% |
| Q1 2024 Q2Q % growth | -0.50 47.37% | -0.61 | 0.11 | 18.30% |
| Q4 2023 Q2Q % growth | -0.60 47.83% | -0.79 | 0.19 | 24.10% |
| Q3 2023 Q2Q % growth | -0.70 26.32% | -0.87 | 0.17 | 19.26% |
| Q2 2023 Q2Q % growth | -0.80 27.27% | -0.94 | 0.14 | 14.75% |
| Q1 2023 Q2Q % growth | -0.95 | -1.13 | 0.18 | 16.09% |
| Q4 2022 Q2Q % growth | -1.15 -9.52% | -1.05 | -0.10 | -10.00% |
| Q3 2022 Q2Q % growth | -0.95 5.00% | -1.11 | 0.16 | 14.36% |
| Q2 2022 Q2Q % growth | -1.10 -29.41% | -1.05 | -0.05 | -4.36% |
| Q1 2022 Q2Q % growth | -0.95 -18.75% | -1.13 | 0.18 | 16.28% |
| Q4 2021 Q2Q % growth | -1.05 -5.00% | -0.97 | -0.08 | -8.36% |
| Q3 2021 Q2Q % growth | -1.00 -33.33% | -1.08 | 0.08 | 7.73% |
| Q2 2021 Q2Q % growth | -0.85 -21.43% | -0.98 | 0.13 | 13.42% |
| Q1 2021 Q2Q % growth | -0.80 -60.00% | -0.95 | 0.15 | 15.97% |
| Q4 2020 Q2Q % growth | -1.00 -53.85% | -0.96 | -0.04 | -4.58% |
| Q3 2020 Q2Q % growth | -0.75 | -0.78 | 0.03 | 4.09% |
| Q2 2020 Q2Q % growth | -0.70 | -0.46 | -0.24 | -52.51% |
| Q1 2020 Q2Q % growth | -0.50 | -0.56 | 0.06 | 10.87% |
| Q4 2019 Q2Q % growth | -0.65 | -0.36 | -0.29 | -82.07% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 8.33% | 42.89% | 14.69% | 16.67% |
| Revenue | N/A | N/A | N/A | N/A |